Top
Summary
All studies
Exclusions
Mortality
Ventilation
ICU
Hospitalization
Serious outcomes
Recovery
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
All thermotherapy studies
 
Feedback
Home
c19early.org COVID-19 treatment researchThermotherapyThermotherapy (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

Outcomes in COVID-19 thermotherapy studies

0 0.5 1 1.5+ All studies 56% 4 217 Improvement, Studies, Patients Relative Risk Mortality 43% 1 105 Ventilation 53% 2 145 ICU admission 76% 1 40 Hospitalization 40% 1 50 Recovery 67% 2 90 Viral clearance 80% 1 50 RCTs 56% 3 195 Late 56% 4 217 Thermotherapy for COVID-19 c19early.org February 2024 after exclusions Favorsthermotherapy Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Huang (RCT) 80% 0.20 [0.01-3.97] oxygen 0/25 2/25 diathermy Improvement, RR [CI] Treatment Control Dominguez-Nicolas 53% 0.47 [0.22-1.01] no improv. 8/17 5/5 LF-ThMS Tian (DB RCT) 84% 0.16 [0.02-1.40] ventilation 1/27 3/13 diathermy Excluded Bonfanti (RCT) -11% 1.11 [0.39-3.19] death 4/9 4/10 Ventilated patients TherMoCoV Mancilla-G.. (RCT) 43% 0.57 [0.22-1.45] death 6/54 10/51 heating pad Tau​2 = 0.00, I​2 = 0.0%, p = 0.026 Late treatment 56% 0.44 [0.22-0.91] 15/123 20/94 56% lower risk All studies 56% 0.44 [0.22-0.91] 15/123 20/94 56% lower risk 4 thermotherapy COVID-19 studies c19early.org February 2024 Tau​2 = 0.00, I​2 = 0.0%, p = 0.026 Effect extraction pre-specified(most serious outcome, see appendix) Favors thermotherapy Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Huang (RCT) 80% 0.20 [0.01-3.97] oxygen 0/25 2/25 diathermy Improvement, RR [CI] Treatment Control Tian (DB RCT) 84% 0.16 [0.02-1.40] ventilation 1/27 3/13 diathermy TherMoCoV Mancilla-G.. (RCT) 43% 0.57 [0.22-1.45] death 6/54 10/51 heating pad Tau​2 = 0.00, I​2 = 0.0%, p = 0.048 Late treatment 56% 0.44 [0.19-0.99] 7/106 15/89 56% lower risk All studies 56% 0.44 [0.19-0.99] 7/106 15/89 56% lower risk 3 thermotherapy COVID-19 studies after exclusions c19early.org February 2024 Tau​2 = 0.00, I​2 = 0.0%, p = 0.048 Effect extraction pre-specified(most serious outcome, see appendix) Favors thermotherapy Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Excluded Bonfanti (RCT) -11% 1.11 [0.39-3.19] 4/9 4/10 Ventilated patients Improvement, RR [CI] Treatment Control TherMoCoV Mancilla-G.. (RCT) 43% 0.57 [0.22-1.45] 6/54 10/51 heating pad Tau​2 = 0.00, I​2 = 0.0%, p = 0.24 Late treatment 43% 0.57 [0.22-1.45] 6/54 10/51 43% lower risk All studies 43% 0.57 [0.22-1.45] 6/54 10/51 43% lower risk 1 thermotherapy COVID-19 mortality result c19early.org February 2024 Tau​2 = 0.00, I​2 = 0.0%, p = 0.24 Favors thermotherapy Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Tian (DB RCT) 84% 0.16 [0.02-1.40] 1/27 3/13 diathermy Improvement, RR [CI] Treatment Control TherMoCoV Mancilla-G.. (RCT) 21% 0.79 [0.26-2.42] 5/54 6/51 heating pad Tau​2 = 0.49, I​2 = 38.8%, p = 0.32 Late treatment 53% 0.47 [0.11-2.02] 6/81 9/64 53% lower risk All studies 53% 0.47 [0.11-2.02] 6/81 9/64 53% lower risk 2 thermotherapy COVID-19 mechanical ventilation results c19early.org February 2024 Tau​2 = 0.49, I​2 = 38.8%, p = 0.32 Favors thermotherapy Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Tian (DB RCT) 76% 0.24 [0.05-1.15] 2/27 4/13 diathermy Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.074 Late treatment 76% 0.24 [0.05-1.15] 2/27 4/13 76% lower risk All studies 76% 0.24 [0.05-1.15] 2/27 4/13 76% lower risk 1 thermotherapy COVID-19 ICU result c19early.org February 2024 Tau​2 = 0.00, I​2 = 0.0%, p = 0.074 Favors thermotherapy Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Huang (RCT) 40% 0.60 [0.16-2.25] hosp. 3/25 5/25 diathermy Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.46 Late treatment 40% 0.60 [0.16-2.25] 3/25 5/25 40% lower risk All studies 40% 0.60 [0.16-2.25] 3/25 5/25 40% lower risk 1 thermotherapy COVID-19 hospitalization result c19early.org February 2024 Tau​2 = 0.00, I​2 = 0.0%, p = 0.46 Favors thermotherapy Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Huang (RCT) 80% 0.20 [0.01-3.97] oxygen 0/25 2/25 diathermy Improvement, RR [CI] Treatment Control Tian (DB RCT) 84% 0.16 [0.02-1.40] ventilation 1/27 3/13 diathermy Excluded Bonfanti (RCT) -11% 1.11 [0.39-3.19] death 4/9 4/10 Ventilated patients TherMoCoV Mancilla-G.. (RCT) 43% 0.57 [0.22-1.45] death 6/54 10/51 heating pad Tau​2 = 0.00, I​2 = 0.0%, p = 0.048 Late treatment 56% 0.44 [0.19-0.99] 7/106 15/89 56% lower risk All studies 56% 0.44 [0.19-0.99] 7/106 15/89 56% lower risk 3 thermotherapy COVID-19 serious outcomes c19early.org February 2024 Tau​2 = 0.00, I​2 = 0.0%, p = 0.048 Effect extraction pre-specified(most serious outcome, see appendix) Favors thermotherapy Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Huang (RCT) 67% 0.33 [0.16-0.70] no recov. 6/25 18/25 diathermy Improvement, RR [CI] Treatment Control Tian (DB RCT) 67% 0.33 [0.15-0.72] no recov. 27 (n) 13 (n) diathermy Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Late treatment 67% 0.33 [0.19-0.57] 6/52 18/38 67% lower risk All studies 67% 0.33 [0.19-0.57] 6/52 18/38 67% lower risk 2 thermotherapy COVID-19 recovery results c19early.org February 2024 Tau​2 = 0.00, I​2 = 0.0%, p < 0.0001 Favors thermotherapy Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Huang (RCT) 80% 0.20 [0.01-3.97] viral+ 0/25 2/25 diathermy Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.29 Late treatment 80% 0.20 [0.01-3.97] 0/25 2/25 80% lower risk All studies 80% 0.20 [0.01-3.97] 0/25 2/25 80% lower risk 1 thermotherapy COVID-19 viral clearance result c19early.org February 2024 Tau​2 = 0.00, I​2 = 0.0%, p = 0.29 Favors thermotherapy Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Huang (RCT) 80% 0.20 [0.01-3.97] oxygen 0/25 2/25 diathermy Improvement, RR [CI] Treatment Control Tian (DB RCT) 84% 0.16 [0.02-1.40] ventilation 1/27 3/13 diathermy Excluded Bonfanti (RCT) -11% 1.11 [0.39-3.19] death 4/9 4/10 Ventilated patients TherMoCoV Mancilla-G.. (RCT) 43% 0.57 [0.22-1.45] death 6/54 10/51 heating pad Tau​2 = 0.00, I​2 = 0.0%, p = 0.048 Late treatment 56% 0.44 [0.19-0.99] 7/106 15/89 56% lower risk All studies 56% 0.44 [0.19-0.99] 7/106 15/89 56% lower risk 3 thermotherapy COVID-19 Randomized Controlled Trials c19early.org February 2024 Tau​2 = 0.00, I​2 = 0.0%, p = 0.048 Effect extraction pre-specified(most serious outcome, see appendix) Favors thermotherapy Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Excluded Bonfanti (RCT) -11% 1.11 [0.39-3.19] 4/9 4/10 Ventilated patients Improvement, RR [CI] Treatment Control TherMoCoV Mancilla-G.. (RCT) 43% 0.57 [0.22-1.45] 6/54 10/51 heating pad Tau​2 = 0.00, I​2 = 0.0%, p = 0.24 Late treatment 43% 0.57 [0.22-1.45] 6/54 10/51 43% lower risk All studies 43% 0.57 [0.22-1.45] 6/54 10/51 43% lower risk 1 thermotherapy COVID-19 RCT mortality result c19early.org February 2024 Tau​2 = 0.00, I​2 = 0.0%, p = 0.24 Favors thermotherapy Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Huang (RCT) 80% 0.20 [0.01-3.97] oxygen 0/25 2/25 diathermy Improvement, RR [CI] Treatment Control Dominguez-Nicolas 53% 0.47 [0.22-1.01] no improv. 8/17 5/5 LF-ThMS Tian (DB RCT) 84% 0.16 [0.02-1.40] ventilation 1/27 3/13 diathermy Excluded Bonfanti (RCT) -11% 1.11 [0.39-3.19] death 4/9 4/10 Ventilated patients TherMoCoV Mancilla-G.. (RCT) 43% 0.57 [0.22-1.45] death 6/54 10/51 heating pad Tau​2 = 0.00, I​2 = 0.0%, p = 0.026 Late treatment 56% 0.44 [0.22-0.91] 15/123 20/94 56% lower risk All studies 56% 0.44 [0.22-0.91] 15/123 20/94 56% lower risk 4 thermotherapy COVID-19 peer reviewed studies c19early.org February 2024 Tau​2 = 0.00, I​2 = 0.0%, p = 0.026 Effect extraction pre-specified(most serious outcome, see appendix) Favors thermotherapy Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Huang (RCT) 80% 0.20 [0.01-3.97] oxygen 0/25 2/25 diathermy Improvement, RR [CI] Treatment Control Huang (RCT) 40% 0.60 [0.16-2.25] hosp. 3/25 5/25 diathermy Huang (RCT) 67% 0.33 [0.16-0.70] no recov. 6/25 18/25 diathermy Huang (RCT) 15% 0.85 [0.72-0.99] recov. time 25 (n) 25 (n) diathermy Huang (RCT) 67% 0.33 [0.12-0.90] no recov. 25 (n) 25 (n) diathermy Huang (RCT) 67% 0.33 [0.17-0.67] no recov. 25 (n) 25 (n) diathermy Huang (RCT) 80% 0.20 [0.01-3.97] viral+ 0/25 2/25 diathermy Huang (RCT) 50% 0.50 [0.14-1.78] viral+ 3/25 6/25 diathermy Huang (RCT) -57% 1.57 [0.73-3.39] viral+ 11/25 7/25 diathermy Huang (RCT) -28% 1.28 [0.98-1.67] viral+ 23/25 18/25 diathermy Dominguez-Nicolas 53% 0.47 [0.22-1.01] no improv. 8/17 5/5 LF-ThMS Dominguez-Nicolas 93% 0.07 [0.01-0.48] no improv. 0/17 3/5 LF-ThMS Dominguez-Nicolas 93% 0.07 [0.01-0.48] no improv. 0/17 3/5 LF-ThMS Dominguez-Nicolas 96% 0.04 [0.00-0.68] no improv. 0/17 5/5 LF-ThMS Dominguez-Nicolas 82% 0.18 [0.07-0.47] no improv. 3/17 5/5 LF-ThMS Dominguez-Nicolas 53% 0.47 [0.22-1.01] no improv. 8/17 5/5 LF-ThMS Dominguez-Nicolas 35% 0.65 [0.30-1.39] no improv. 11/17 5/5 LF-ThMS Dominguez-Nicolas 35% 0.65 [0.30-1.39] no improv. 11/17 5/5 LF-ThMS Dominguez-Nicolas 18% 0.82 [0.59-1.15] no improv. 14/17 5/5 LF-ThMS Dominguez-Nicolas 18% 0.82 [0.59-1.15] no improv. 14/17 5/5 LF-ThMS Dominguez-Nicolas 12% 0.88 [0.65-1.20] no improv. 15/17 5/5 LF-ThMS Dominguez-Nicolas 6% 0.94 [0.71-1.24] no improv. 16/17 5/5 LF-ThMS Tian (DB RCT) 84% 0.16 [0.02-1.40] ventilation 1/27 3/13 diathermy Tian (DB RCT) 76% 0.24 [0.05-1.15] ICU 2/27 4/13 diathermy Tian (DB RCT) 67% 0.33 [0.15-0.72] no recov. 27 (n) 13 (n) diathermy Tian (DB RCT) 73% 0.27 [0.11-0.67] no recov. 27 (n) 13 (n) diathermy Excluded Bonfanti (RCT) -11% 1.11 [0.39-3.19] death 4/9 4/10 Ventilated patients Excluded Bonfanti (RCT) 26% 0.74 [0.16-3.48] death 2/9 3/10 Ventilated patients TherMoCoV Mancilla-G.. (RCT) 43% 0.57 [0.22-1.45] death 6/54 10/51 heating pad TherMoCoV Mancilla-G.. (RCT) 43% 0.57 [0.14-2.25] death 3/54 5/51 heating pad TherMoCoV Mancilla-G.. (RCT) 21% 0.79 [0.26-2.42] ventilation 5/54 6/51 heating pad TherMoCoV Mancilla-G.. (RCT) 17% 0.83 [0.45-1.52] progression 14/54 16/51 heating pad Thermotherapy COVID-19 outcomes c19early.org February 2024 Favors thermotherapy Favors control
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit